<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[0, 6] Safety, tolerability, and immunogenicity<br>[75, 76] impact<br>[99, 103] immunity and safety profiles<br>[119, 122] Immunogenicity was evaluated<br>[123, 138] VZV interferon-gamma (IFN-) enzyme-linked immunospot (ELISPOT) assay<br>[139, 151] VZV glycoprotein enzyme-linked immunosorbent antibody (gpELISA) assay.<br>[169, 173] vaccine-related AEs<br>[175, 196] VZV IFN- ELISPOT geometric mean count (GMC) of spot-forming cells per 10(6) peripheral blood mononuclear cells<br>[229, 230] GMC<br>[240, 241] GMC<br>[253, 256] peak ELISPOT response<br>[265, 272] gpELISA geometric mean titers (GMTs)<br>[290, 291] Correlation<br>[293, 298] IFN- ELISPOT and gpELISA assays<br>[306, 311] well-tolerated and immunogenic<br>[323, 326] generally safe,<br>[329, 334] boost VZV-specific immunity<br></td>
<td width=33%>
[0, 6] Safety, tolerability, and immunogenicity<br>[75, 76] impact<br>[99, 103] immunity and safety profiles<br>[119, 122] Immunogenicity was evaluated<br>[123, 138] VZV interferon-gamma (IFN-) enzyme-linked immunospot (ELISPOT) assay<br>[139, 151] VZV glycoprotein enzyme-linked immunosorbent antibody (gpELISA) assay.<br>[169, 173] vaccine-related AEs<br>[175, 196] VZV IFN- ELISPOT geometric mean count (GMC) of spot-forming cells per 10(6) peripheral blood mononuclear cells<br>[229, 230] GMC<br>[240, 241] GMC<br>[253, 256] peak ELISPOT response<br>[265, 272] gpELISA geometric mean titers (GMTs)<br>[290, 291] Correlation<br>[293, 298] IFN- ELISPOT and gpELISA assays<br>[306, 311] well-tolerated and immunogenic<br>[323, 326] generally safe,<br>[329, 334] boost VZV-specific immunity<br></td>
<td width=33%>
[0, 6] Safety, tolerability, and immunogenicity<br>[24, 27] Incidence and severity<br>[75, 77] impact of<br>[99, 103] immunity and safety profiles<br>[119, 151] Immunogenicity was evaluated using VZV interferon-gamma (IFN-) enzyme-linked immunospot (ELISPOT) assay and VZV glycoprotein enzyme-linked immunosorbent antibody (gpELISA) assay.<br>[151, 156] Adverse experiences (AEs)<br>[162, 166] Report Card.
<br>[167, 175] No serious vaccine-related AEs occurred.<br>[175, 197] VZV IFN- ELISPOT geometric mean count (GMC) of spot-forming cells per 10(6) peripheral blood mononuclear cells increased<br>[229, 230] GMC<br>[240, 241] GMC<br>[253, 256] peak ELISPOT response<br>[265, 272] gpELISA geometric mean titers (GMTs)<br>[290, 301] Correlation between the IFN- ELISPOT and gpELISA assays was poor.<br>[306, 311] well-tolerated and immunogenic<br>[323, 334] generally safe, but did not boost VZV-specific immunity<br></td>
</tr>
